Evidence map›Paper›PMID 34834413›Full record

ArticleJournal of personalized medicine2021

Multiphoton Microscopy for Identifying Collagen Signatures Associated with Biochemical Recurrence in Prostate Cancer Patients.

Ina P Pavlova, Sujit S Nair, Dara Lundon, Stanislaw Sobotka, Reza Roshandel, Patrick-Julien Treacy, Parita Ratnani, Rachel Brody, Jonathan I Epstein, Gustavo E Ayala and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Ina P PavlovaDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Sujit S NairDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-3039-523X
Dara LundonDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-4425-3520
Stanislaw SobotkaDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-0200-5078
Reza RoshandelDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Patrick-Julien TreacyDepartment of Urology, Pasteur 2 University Hospital of Nice, 06000 Nice, France.ORCID 0000-0001-6631-1117
Parita RatnaniDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Rachel BrodyDepartment of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jonathan I EpsteinDepartment of Pathology, Urology and Oncology, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
Gustavo E AyalaDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX 77030, USA.
Natasha KyprianouDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-8713-3599
Ashutosh K TewariDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Icahn School of Medicine at Mount Sinai · USHôpital Pasteur · FRJohns Hopkins Hospital · USThe University of Texas Health Science Center at Houston · US

Funding

Treatment-Induced Phenotypic Reprogramming in Prostate CancerR01CA232574 · NCI · UNIVERSITY OF KENTUCKY · PI KYPRIANOU, NATASHA · 2019 to 2023
$2.2M
NCI NIH HHS R01 CA232574
6 · The paper itself

Abstract

Prostate cancer is a heterogeneous disease that remains dormant for long periods or acts aggressively with poor clinical outcomes. Identifying aggressive prostate tumor behavior using current glandular-focused histopathological criteria is challenging. Recent evidence has implicated the stroma in modulating prostate tumor behavior and in predicting post-surgical outcomes. However, the emergence of stromal signatures has been limited, due in part to the lack of adoption of imaging modalities for stromal-specific profiling. Herein, label-free multiphoton microscopy (MPM), with its ability to image tissue with stromal-specific contrast, is used to identify prostate stromal features associated with aggressive tumor behavior and clinical outcome. MPM was performed on unstained prostatectomy specimens from 59 patients and on biopsy specimens from 17 patients with known post-surgery recurrence status. MPM-identified collagen content, organization, and morphological tumor signatures were extracted for each patient and screened for association with recurrent disease. Compared to tumors from patients whose disease did not recur, tumors from patients with recurrent disease exhibited higher MPM-identified collagen amount and collagen fiber intensity signal and width. Our study shows an association between MPM-identified stromal collagen features of prostate tumors and post-surgical disease recurrence, suggesting their potential for prostate cancer risk assessment.

Indexed as

collagen signaturesoptical microscopyprognosisprostate cancerreactive stroma

Identifiers

PMID34834413
PMCPMC8619628
OpenAlexW3209700601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.